Small molecules capable of modulating methionine adenosyltransferase 2A (MAT2A) are of
significant interest in precise cancer therapeutics. Herein, we raised the hole–electron …

Abstract Methionine adenosyltransferase 2A (MAT2A) has been indicated as a drug target
for oncology indications. Clinical trials with MAT2A inhibitors are currently on-going. Here, a …

MAT2a is a methionine adenosyltransferase that synthesizes the essential metabolite S-
adenosylmethionine (SAM) from methionine and ATP. Tumors bearing the co-deletion of …

Inhibition of methionine adenosyltransferase 2A (MAT2A) has received significant interest
because of its implication as a synthetic lethal target in methylthioadenosine phosphorylase …

The methionine adenosyltransferase MAT2A catalyzes the synthesis of the methyl donor S-
adenosylmethionine (SAM) and thereby regulates critical aspects of metabolism and …

Inhibition of methionine adenosyltransferase 2A (MAT2A) in cancers with a deletion of
methylthioadenosine phosphorylase (MTAP) gene leads to synthetic lethality, thus receiving …

Methionine adenosyltransferase 2A (MAT2A) is a rate-limiting enzyme in the methionine
cycle that primarily catalyzes the synthesis of S-adenosylmethionine (SAM) from methionine …

Inhibition of the S-adenosyl methionine (SAM)-producing metabolic enzyme, methionine
adenosyltransferase 2A (MAT2A), has received significant interest in the field of medicinal …

Synthetic lethality has recently emerged as a new approach for the treatment of mutated
genes that were previously considered undruggable. Targeting methionine …

The metabolic enzyme methionine adenosyltransferase 2A (MAT2A) was recently implicated
as a synthetic lethal target in cancers with deletion of the methylthioadenosine …